Download MendeleyInvestigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach.
Ryan, A., Polycarpou, E., Lack, N.A., Evangelopoulos, D., Sieg, C., Halman, A., Bhakta, S., Eleftheriadou, O., McHugh, T.D., Keany, S., Lowe, E.D., Ballet, R., Abuhammad, A., Jacobs, W.R., Ciulli, A., Sim, E.(2017) Br J Pharmacol 174: 2209-2224
- PubMed: 28380256
- DOI: https://doi.org/10.1111/bph.13810
- Primary Citation of Related Structures:
5JZ9, 5JZB, 5JZS - PubMed Abstract:
With the emergence of extensively drug-resistant tuberculosis, there is a need for new anti-tubercular drugs that work through novel mechanisms of action. The meta cleavage product hydrolase, HsaD, has been demonstrated to be critical for the survival of Mycobacterium tuberculosis in macrophages and is encoded in an operon involved in cholesterol catabolism, which is identical in M. tuberculosis and M. bovis BCG.
Organizational Affiliation:
Faculty of Science, Engineering and Computing, Kingston University London, Kingston upon Thames, UK.
